NetWorth
LeaderPortfolio
Dae-in
Yoon Dae-in
Rank #2749
SOUTH KOREA•Healthcare•Biotech

Yoon Dae-in

Net Worth
$1.387B
+8.45% (24h)
Yoon Dae-in, a prominent figure in South Korea's biotech industry, is the chairman of Sam Chun Dang Pharm (SCD). Born in 1950, Yoon has dedicated his career to the healthcare sector. He acquired Chosun Sam Chun Dang in 1986 after completing his MBA, using family funds. His achievements include leading SCD in the development of innovative pharmaceutical ingredients and drug delivery systems, such as the S-Pass technology. As of March 2026, Yoon's estimated net worth is $4.9 Billion, reflecting his successful ventures in the biotech field.

How to read Yoon Dae-in's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Yoon Dae-in, we anchor the narrative to Biotech and Biotech, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $1.387B alongside global rank #2749, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (SOUTH KOREA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Yoon Dae-in was born in 1950. After completing his MBA studies, Yoon used family funds to acquire Chosun Sam Chun Dang. He has a Bachelor of Business Administration from Seoul National University and a Master of Business Administration from Long Island University.

Rise to Success

Yoon Dae-in's career highlights his strategic acquisition and leadership of Sam Chun Dang Pharm (SCD). Under his guidance, the company has focused on developing active pharmaceutical ingredients (APIs) for treatments, including those for dry-eye disease and high blood pressure. SCD also developed innovative drug delivery systems, such as S-Pass, which transforms injectable medicines into oral pills.

Key Business Strategies

Yoon's key business strategy involves innovative drug development and strategic partnerships. A notable achievement includes the January 2026 agreement between SCD and Japanese big pharma Daiichi Sankyo to co-develop and commercialize a weight-loss pill in Japan, utilizing S-Pass technology. This collaboration showcases Yoon's ability to foster international partnerships and expand market reach.

Philanthropy

While specific amounts are not readily available, Yoon Dae-in's contributions likely extend beyond business to philanthropic endeavors, reflecting his commitment to societal betterment. As a key figure in the biotechnology field, Yoon has likely been involved in various initiatives through Sam Chun Dang Pharm, supporting medical research and public health programs in South Korea.

Career Timeline

2026

Signed agreement with Daiichi Sankyo

SCD signed an agreement with Japanese big pharma Daiichi Sankyo to jointly develop and commercialize SCD's weight-loss pill in Japan.

1986

Acquired Chosun Sam Chun Dang

Yoon used family funds to acquire Chosun Sam Chun Dang after completing his MBA studies.

Philanthropic Impact

HealthcareUndisclosed

General Support

Likely involved in medical research and public health programs.

Key Business Ventures & Holdings

CompanyStakeValue
So Hwa Corp56.52%—

Net Worth History

In-Depth Analysis

Early Life

Yoon Dae-in was born in 1950. After completing his MBA studies, Yoon used family funds to acquire Chosun Sam Chun Dang. He has a Bachelor of Business Administration from Seoul National University and a Master of Business Administration from Long Island University.

Rise to Success

Yoon Dae-in's career highlights his strategic acquisition and leadership of Sam Chun Dang Pharm (SCD). Under his guidance, the company has focused on developing active pharmaceutical ingredients (APIs) for treatments, including those for dry-eye disease and high blood pressure. SCD also developed innovative drug delivery systems, such as S-Pass, which transforms injectable medicines into oral pills.

Key Business Strategies

Yoon's key business strategy involves innovative drug development and strategic partnerships. A notable achievement includes the January 2026 agreement between SCD and Japanese big pharma Daiichi Sankyo to co-develop and commercialize a weight-loss pill in Japan, utilizing S-Pass technology. This collaboration showcases Yoon's ability to foster international partnerships and expand market reach.

Philanthropy

While specific amounts are not readily available, Yoon Dae-in's contributions likely extend beyond business to philanthropic endeavors, reflecting his commitment to societal betterment. As a key figure in the biotechnology field, Yoon has likely been involved in various initiatives through Sam Chun Dang Pharm, supporting medical research and public health programs in South Korea.

Data Sources & Methodology

Figures for Yoon Dae-in are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom